- Home
- Signaling Pathways
- GPCR/G protein
- Adrenergic Receptor
- (S)-(-)-Propranolol hydrochloride
(S)-(-)-Propranolol hydrochloride
(S)-(-)-Propranolol hydrochloride is a more active enantiomer of propranolol, acting as a?β-adrenoceptor antagonist?with log Kd values being -8.16, -9.08 and -6.93 for human β1-, β2- and β3-adrenoceptors stably expressed in Chinese hamster ovary cells, respectively. β-Adrenoceptor antagonists are one of the most commonly used classes of drugs in cardiovascular medicine (hypertension, ischemic heart disease and heart failure) as well as in the management of anxiety, migraine and glaucoma. In addition, (S)-(-)-propranolol hydrochloride is also a non-specific serotonin receptor antagonist, capable of inhibiting the behavioral responses to increased brain 5-hydroxytryptamine (5-HT).?
References:
1.?Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. British Journal of Pharmacology, 2005, 144(3): 317-322.
2.?Costain DW, Green AR. beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. British Journal of Pharmacology, 1978, 64(2): 193-200.
3.?Barrett AM, Cullum VA. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. British Journal of Pharmacology, 1968, 34(1): 43-55.
Physical Appearance | A solid |
Storage | Store at RT |
M.Wt | 295.81 |
Cas No. | 4199-10-4 |
Formula | C16H21NO2·HCl |
Solubility | ≥15.65 mg/mL in H2O; ≥2.9 mg/mL in EtOH with gentle warming and ultrasonic; ≥57.5 mg/mL in DMSO |
Chemical Name | (S)-1-(isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol hydrochloride |
SDF | Download SDF |
Canonical SMILES | O[C@H](COC1=CC=CC2=CC=CC=C12)CNC(C)C.Cl |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Animal experiment:[3] | |
Animal models |
Cats anaesthetized with halothane |
Dosage form |
From 0.05 mg/kg to the dose at which the arrhythmia to adrenaline was abolished Given intravenously |
Applications |
Both (S)-(-)-propranolol and (S)-(+)-propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (S)- (-)-propranolol was 0.09 ± 0.02 mg/kg whereas that of (S)-(+)-propranolol was 4.2 ± 1.2 mg/kg. |
Note |
The technical data provided above is for reference only. |
References: 1. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. British Journal of Pharmacology, 2005, 144(3): 317-322. 2. Costain DW, Green AR. beta-Adrenoceptor antagonists inhibit the behavioural responses of rats to increased brain 5-hydroxytryptamine. British Journal of Pharmacology, 1978, 64(2): 193-200. 3. Barrett AM, Cullum VA. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. British Journal of Pharmacology, 1968, 34(1): 43-55. |
Quality Control & MSDS
- View current batch: